Edap Tms SA 8-K filings

EDAP TMS S.A. announced the pricing of an underwritten public offering of 8,425,000 American Depositary Shares (ADSs) at $4.75 per ADS, expecting to raise approximately $37.1 million in net proceeds.

FocalTherics announced preliminary Q2 2026 financial results showing significant revenue growth and progress in expanding its Focal One platform into BPH and endometriosis indications.

EDAP TMS shareholders approved all director re-elections, financial statements, and updated corporate bylaws at the 2026 Annual General Meeting.

EDAP TMS S.A. announced its rebranding to FocalTherics, a new ticker symbol FOCL, and a strategic shift to focus exclusively on high-growth robotic focal therapy by classifying legacy segments as discontinued operations.

EDAP TMS SA announced strong first quarter 2026 financial results, driven by a significant 78% year-over-year increase in High-Intensity Focused Ultrasound (HIFU) revenue, reaching $11.6 million.

EDAP TMS SA has triggered the second tranche of its European Investment Bank credit facility, drawing 12 million euros and issuing associated warrants.

EDAP TMS SA announced record fourth quarter and full-year 2025 HIFU revenue, driven by increased Focal One system sales and U.S. procedure growth, while reiterating its 2026 revenue guidance.

EDAP TMS SA presented at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference, showcasing accelerated adoption and strong clinical evidence for its Focal One Robotic HIFU technology.

EDAP TMS S.A. announced the appointment of David Horn, a seasoned finance and healthcare industry executive, to its Board of Directors following the amicable resignation of Glen French.

EDAP TMS SA announced preliminary record fourth quarter and full-year 2025 HIFU revenue, driven by strong system placements and accelerating procedure growth, alongside positive 2026 revenue guidance.